Enhancing Prostate Cancer Genomics with AI-Powered Morphometric Analysis October 23, 2025 By Myriad Oncology™ As AI becomes more widely used in medicine, prostate cancer is emerging as one of the areas where its impact is most tangible. In path... Continue Reading
Myriad Genetics’ continued investment in molecular residual disease (MRD) testing drives new patents granted October 7, 2025 Myriad Genetics is strengthening its position in the high-growth molecular residual disease (MRD) testing market with newly granted patents that expand protect... Continue Reading
Using Prostate Cancer Gene Testing to Guide Treatment Decisions: Insights as We Head into 2026 October 1, 2025 By Dr. Christopher Lee, Cancer Care Northwest As clinicians caring for patients with prostate cancer, we all hear the question asked frequently of us “wha... Continue Reading
Addressing Provider Misconceptions in Ovarian Cancer Genetic Testing September 30, 2025 By John Chan, MD, Gynecologic Oncologist, Sutter Health Despite major advances for genetic testing in ovarian cancer, misconceptions persist about when and... Continue Reading
How Genomic Testing is Transforming Treatment Decisions in Intermediate-Risk Prostate Cancer September 4, 2025 By Lauren Lenz, Christina Nakamoto, & Robert Finch In men with prostate cancer, few decisions are as difficult—or as emotionally charged—as choosing... Continue Reading
50 Years After the Monoclonal Antibody Breakthrough: Why Precision Medicine Still Needs Reinventing September 4, 2025 In July 1975, a scientific paper in Nature by César Milstein and Georges Köhler described how to produce monoclonal antibodies: highly specific, identical im... Continue Reading
What Does RNA Analysis Actually Add to Hereditary Cancer Testing? July 7, 2025 Not All RNA Analysis Is Created Equal Genetic testing has transformed how we understand cancer risk. For nearly three decades, DNA-based analysis has been t... Continue Reading